

**Patient Name:**

Accession#: R10000  
Birthdate: 3/2/2020  
MRN#:  
Specimen:  
Collected: 11/1/2021  
Reported: 01/07/2022

**Targeted Long Chain Dicarboxylic Acylcarnitine Panel**

**RESULTS**

ANALYTE	REFERENCE RANGE	RESULT	FLAG
hexadecanedioylcarnitine (C16:DC)	(0 to 0.050)	0.007	
octadecenedioylcarnitine (C18:1:DC)	(0 to 0.041)	0.004	
octadecanedioylcarnitine (C18:DC)	(0 to 0.028)	0.007	
eicosanedioylcarnitine (C20:DC)	(0 to 0.004)	0.000	
docosanedioylcarnitine (C22:DC)	(0 to 0.002)	0.000	

\*values in micromoles/L

**INTERPRETATION**

Mock report

**ASSAY INFORMATION**

**Method**

Analysis is performed by liquid chromatography tandem mass spectrometry (LC-MS/MS) on underivatized specimens.

For more information visit: <https://medicine.iu.edu/iubgl>

**Limitations/Disclaimer**

False negative results can occur in rare situations when diet, treatment or secondary carnitine depletion causes acylcarnitine levels to appear normal in an affected individual.

This test was developed and its performance characteristics determined by Indiana University Biochemical Genetics Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. The laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) as qualified to perform high complexity clinical laboratory testing. CLIA# 15D0647198 • CAP# 1678930

**ELECTRONICALLY SIGNED BY**

Marcus J. Miller PhD FACMG, Director of the IU Biochemical Genetics Laboratory, 01/07/2022